Gain Therapeutics, Inc. (GANX)
1.79
-0.04
(-2.19%)
USD |
NASDAQ |
Sep 09, 13:18
Gain Therapeutics Max Drawdown (5Y) : 94.08% for Aug. 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| August 31, 2026 | 94.08% |
| July 31, 2026 | 94.08% |
| June 30, 2026 | 94.08% |
| May 31, 2026 | 94.08% |
| April 30, 2026 | 94.08% |
| March 31, 2026 | 94.08% |
| February 28, 2026 | 94.08% |
| January 31, 2026 | 94.08% |
| December 31, 2025 | 94.08% |
| Date | Value |
|---|---|
| November 30, 2025 | 94.08% |
| October 31, 2025 | 94.08% |
| September 30, 2025 | 94.08% |
| August 31, 2025 | 94.08% |
| July 31, 2025 | 94.08% |
| June 30, 2025 | 94.08% |
| May 31, 2025 | 94.08% |
| April 30, 2025 | 94.08% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 77.18% |
| Alnylam Pharmaceuticals, Inc. | 58.17% |
| Anika Therapeutics, Inc. | 83.15% |
| Savara, Inc. | 96.98% |
| Vericel Corp. | 73.97% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -30.99 |
| Beta (5Y) | 0.2042 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 82.16% |
| Historical Sharpe Ratio (5Y) | -0.3546 |
| Historical Sortino (5Y) | -0.7387 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 32.12% |